Search

John S Debenham

from Scotch Plains, NJ
Age ~55
Get Report
Also known as:
John Steele Debenham
Phone and address:
2 Blue Ridge Cir, Scotch Plains, NJ 07076
(908) 561-6622
Related to:
Harry Lavelle, 80Sherry Alling, 39Leonard P Lavelle, 44W Debenham, 57Adaria R Debenham, 85Judy M Davis, 78Martin L Davis, 81Sheryl D DebenhamJay B Davis, 68Sheryl D Debenham, 51Wstuart Rd Debenham, 57Kara E Byrd, 48
Connected to:
Brad L Debenham, 56James E Debenham, 59Margaret H Debenham, 113William H Debenham, 74Justin P Debenning, 43David J Deberardis, 49Denise M Deberardino, 69Georgia D Deberardinis, 62Marc A Deberardino, 74Mark P Deberardini, 54

John Debenham Phones & Addresses

  • 2 Blue Ridge Cir, Scotch Plains, NJ 07076 (908) 561-6622
  • 805 Ava Dr, Kingsport, TN 37663 (423) 239-5137
  • 220 Bridgefield Pl, Durham, NC 27705 (919) 383-0191
  • Bedminster, NJ
  • Coraopolis, PA
  • Sewickley, PA
  • Saint Louis, MO
  • Union, NJ
  • 2 Blue Ridge Cir, Scotch Plains, NJ 07076 (908) 309-8307

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Emails

d***[email protected]

Public records

Vehicle Records

John Debenham

View page
Address:
2 Blue Rdg Cir, Scotch Plains, NJ 07076
Phone:
(908) 757-7926
VIN:
1FAHP3H29CL241022
Make:
FORD
Model:
FOCUS
Year:
2012

Publications

Isbn (Books And Publications)

Knowledge Systems Design

View page
Author

John K. Debenham

ISBN #

0135164281

Professional Practice in ARtificial Intelligence: IFIP 19th World Computer Congress, TC 12 Professional Practice Stream, August 21-24, 2006, Santiago, Chile

View page
Author

John Debenham

ISBN #

0387346554

Database And Expert Systems Applications: 16th International Conference, DEXA 2005, Copenhagen, Denmark, August 22-26, 2005, Proceedings

View page
Author

John Debenham

ISBN #

3540285660

Knowledge Engineering : Unifying Knowledge Base and Database Design

View page
Author

John Debenham

ISBN #

3540637656

Us Patents

Corn Fiber For The Production Of Advanced Chemicals And Materials:arabinoxylan And Arabinoxylan Derivatives Made Therefrom

View page
US Patent:
6388069, May 14, 2002
Filed:
Feb 10, 2000
Appl. No.:
09/502077
Inventors:
Charles M. Buchanan - Kingsport TN
Norma L. Buchanan - Kingsport TN
John S. Debenham - Kingsport TN
Michael C. Shelton - Kingsport TN
Matthew D. Wood - Gray TN
Assignee:
Eastman Chemical Company - Kingsport TN
International Classification:
C12P 1900
US Classification:
536 72, 435 74, 536 56, 536 58, 536 84, 5361231
Abstract:
In one aspect, the invention provides a method of extracting arabinoxylan from corn fiber wherein the method comprises the steps of: (a) heating an aqueous mixture of corn fiber and a liquid; (b) contacting the mixture of step (a) with a protease enzyme, thereby providing a proteolyzed corn fiber and a liquid; (c) separating the liquid from the proteolyzed corn fiber; (d) contacting the proteolyzed corn fiber at least once with an alkaline extractant, thereby providing an insoluble cellulose material and a liquid comprising arabinoxylan; (e) separating the insoluble cellulose material from the liquid comprising arabinoxylan; and (f) reducing the volume of the liquid comprising arabinoxylan by removing excess alkaline extractant, thereby providing a concentrated liquid comprising from about 10% to about 50% solids, wherein the solids comprise arabinoxylan. In a further aspect, the invention provides methods of preparing novel arabinoxylan esters and ethers. Still further, the invention provides novel arabinoxylan esters and ethers.

Corn Fiber For The Production Of Advanced Chemicals And Materials: Derivatizable Cellulose And Cellulose Derivatives Made Therefrom

View page
US Patent:
6586212, Jul 1, 2003
Filed:
Feb 10, 2000
Appl. No.:
09/502094
Inventors:
Charles M. Buchanan - Kingsport TN
Norma L. Buchanan - Kingsport TN
John S. Debenham - Kingsport TN
Michael C. Shelton - Kingsport TN
Matthew D. Wood - Gray TN
Assignee:
Eastman Chemical Company - Kingsport TN
International Classification:
C12P 1904
US Classification:
435101, 435 72, 435264, 435274, 435277
Abstract:
The invention provides a method of obtaining a cellulose material from corn fiber wherein the method comprises the steps of: (a) heating a mixture of corn fiber and a liquid; (b) contacting the mixture of step (a) with a protease enzyme, thereby providing a proteolyzed corn fiber and a liquid; (c) separating the liquid from the proteolyzed corn fiber; (d) contacting the proteolyzed corn fiber at least once with an alkaline extractant, thereby providing an insoluble cellulose material and a first liquid comprising arabinoxylan; (e) separating the insoluble cellulose material from the first liquid comprising arabinoxylan at a temperature of at or above about 60Â C. ; and (f) rinsing the insoluble cellulose material to remove essentially all alkali, thereby providing a cellulose material having a cellulose content of at least about 50% and consisting essentially of cellulose I. Cellulose esters and ethers are also prepared from the derivatizable cellulose prepared according to the methods herein.

Methods Of Separating A Corn Fiber Lipid Fraction From Corn Fiber

View page
US Patent:
6589760, Jul 8, 2003
Filed:
Feb 10, 2000
Appl. No.:
09/501917
Inventors:
Charles M. Buchanan - Kingsport TN
Norma L. Buchanan - Kingsport TN
John S. Debenham - Kingsport TN
Michael C. Shelton - Kingsport TN
Matthew D. Wood - Gray TN
Assignee:
Eastman Chemical Company - Kingsport TN
International Classification:
C12Q 137
US Classification:
435 23, 424750, 552545
Abstract:
The invention provides a method of separating from corn fiber a lipid fraction having phytosterol esters and phytosterols where the method has the steps of: (a) heating an aqueous mixture of unground corn fiber; (b) contacting the mixture of step (a) with at least one enzyme suitable for digesting starch for a time and at a temperature suitable to provide a mixture of an essentially destarched corn fiber and a liquid comprising soluble carbohydrates; (c) contacting the mixture of step (a) or (b) with a protease enzyme to provide a proteolyzed corn fiber and a liquid; (d) separating the liquid of step (c) from the corn fiber to provide a destarched, proteolyzed corn fiber; and (e) extracting the destarched, proteolyzed corn fiber with at least one organic solvent. A corn fiber lipid fraction/organic solvent solution having phytosterol esters and phytosterols is provided. The invention also provides a corn fiber lipid fraction containing phytosterols and phytosterol esters obtained via solvent extraction of a proteolyzed corn fiber.

Methods Of Preparing Disaccharide And Trisaccharide C6-C12 Fatty Acid Esters With High Alpha Content And Materials Therefrom

View page
US Patent:
6667397, Dec 23, 2003
Filed:
Aug 20, 2001
Appl. No.:
09/933409
Inventors:
John Steele Debenham - Kingsport TN
Charles Michael Buchanan - Kingsport TN
Matthew Davie Wood - Gray TN
Michael Orlando Malcolm - Kingsport TN
Mary Kathleen Moore - Jonesborough TN
Assignee:
Eastman Chemical Company - Kingsport TN
International Classification:
C07H 1306
US Classification:
536124, 536 111, 53612313
Abstract:
The present invention provides chemical processes for the preparation of disaccharide and trisaccharide C to C fatty acid esters having a high alpha content. Yet still further, the invention provides materials prepared by the processes disclosed herein.

Substituted Furo[2,3-B]Pyridine Derivatives

View page
US Patent:
7091216, Aug 15, 2006
Filed:
Aug 1, 2003
Appl. No.:
10/521821
Inventors:
Richard B. Toupence - South Plainfield NJ, US
John S. Debenham - Scotch Plains NJ, US
Mark T. Goulet - Westfield NJ, US
Thomas F. Walsh - Watchung NJ, US
Shrenik K. Shah - Metuchen NJ, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
A61K 31/44
C07D 409/02
US Classification:
514302, 546115
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted 2,3-Diphenyl Pyridines

View page
US Patent:
7271266, Sep 18, 2007
Filed:
Mar 24, 2003
Appl. No.:
10/508043
Inventors:
Paul E. Finke - Milltown NJ, US
Laura C. Meurer - Scotch Plains NJ, US
John S. Debenham - Scotch Plains NJ, US
Richard B. Toupence - South Plainfield NJ, US
Thomas F. Walsh - Watchung NJ, US
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07D 211/82
C07D 211/60
US Classification:
546336, 5462281
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted Naphthyridinone Derivatives

View page
US Patent:
7728141, Jun 1, 2010
Filed:
Oct 29, 2004
Appl. No.:
10/576796
Inventors:
John S. Debenham - Scotch Plains NJ, US
George A. Doss - Westfield NJ, US
Thomas F. Walsh - Watchung NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 471/04
A61K 31/4375
US Classification:
546123, 514300
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Substituted Pyrano[2,3-B]Pyridine Derivatives As Cannabinoid-1 Receptor Modulators

View page
US Patent:
7999107, Aug 16, 2011
Filed:
Jan 16, 2008
Appl. No.:
12/009114
Inventors:
John S. Debenham - Scotch Plains NJ, US
Jeffrey J. Hale - Westfield NJ, US
Pei Huo - Millburn NJ, US
Thomas F. Walsh - Watchung NJ, US
Lin Yan - East Brunswick NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 491/052
A61K 31/436
US Classification:
546115, 546116, 514302
Abstract:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, Huntington's disease movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, cirrhosis of the liver, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and the promotion of wakefulness.
Control profile
John S Debenham from Scotch Plains, NJ, age ~55 Get Report